Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Private Capital Management LLC

Private Capital Management LLC lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 517,418 shares of the medical equipment provider's stock after selling 17,975 shares during the quarter. Lantheus comprises about 11.3% of Private Capital Management LLC's investment portfolio, making the stock its 3rd largest position. Private Capital Management LLC owned approximately 0.74% of Lantheus worth $56,787,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC bought a new stake in shares of Lantheus during the third quarter worth approximately $1,066,000. Massachusetts Financial Services Co. MA acquired a new position in Lantheus in the third quarter valued at approximately $25,955,000. Van ECK Associates Corp boosted its stake in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock valued at $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock worth $1,041,000 after acquiring an additional 3,772 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Remove Ads

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.50% of the company's stock.

Lantheus Trading Up 3.5 %

Shares of NASDAQ:LNTH traded up $3.31 during trading on Tuesday, hitting $98.17. 1,214,518 shares of the company's stock traded hands, compared to its average volume of 900,587. The company has a 50-day moving average price of $89.97 and a 200-day moving average price of $96.73. Lantheus Holdings, Inc. has a 52 week low of $56.44 and a 52 week high of $126.89. The company has a market cap of $6.72 billion, a price-to-earnings ratio of 16.33 and a beta of 0.44.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Truist Financial raised their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $132.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.